Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

http://jamanetwork.com/journals/jamaoncology/article-abstract/2565702

http://www.nejm.org/doi/full/10.1056/NEJMoa1607427 Strosberg J 1 ,  El-Haddad G 1 ,  Wolin E 1 ,  Hendifar A 1 ,  Yao J 1 ,  Chasen B 1 ,  Mittra E 1 ,  Kunz PL 1 ,  Kulke MH 1 ,  Jacene H 1 ,  Bushnell D 1 ,  O'Dorisio TM 1 ,  Baum RP 1 ,  Kulkarni HR 1 ,  Caplin M 1 ,  Lebtahi R 1 ,  Hobday T 1 ,  Delpassand E 1 ,  Van Cutsem E 1 ,  Benson A 1 ,  Srirajaskanthan R 1 ,  Pavel M 1 ,  Mora J 1 ,  Berlin J 1 ,  Grande E 1 ,  Reed N 1 ,  Seregni E 1 ,  Öberg K 1 ,  Lopera Sierra M 1 ,  Santoro P 1 ,  Thevenet T 1 ,  Erion JL 1 ,  Ruszniewski P 1 ,  Kwekkeboom D 1 ,  Krenning E 1 ;  NETTER-1  Trial  Investigators . Author information Abstract Background Patients with advanced  midgut   neuroendocrine   tumors  who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled  trial  evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatost

http://ascopubs.org/doi/pdf/10.1200/JCO.2016.68.6907